4D Molecular Therapeutics appoints Noriyuki Kasahara as Chief Scientific Officer effective Jan 2, 2024

4D Molecular Therapeutics, Inc.

Noriyuki Kasahara, M.D., Ph.D., appointed CSO effective January 2, 2024.
Kasahara resigned from the Board and as Chair of the Science and Technology Committee on January 1, 2024.
Resignation not due to any disagreement with the Company or Board.
He transitions from Board member to executive officer role.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Noriyuki Kasahara

Chief Scientific Officer

FDMT · 4D Molecular Therapeutics, Inc.

Effective: 2024-01-02
Filed: January 4, 2024, 6:59 PM ET

Effective as of January 2, 2024, Noriyuki Kasahara, M.D., Ph.D., has been appointed by the Board of Directors (the “Board”) of 4D Molecular Therapeutics, Inc. (the “Company”) as Chief Scientific Officer of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Noriyuki Kasahara was appointed as Chief Scientific Officer at 4D Molecular Therapeutics, Inc..

Action: appointed
Role: Chief Scientific Officer

Exact text from the filing

Effective as of January 2, 2024, Noriyuki Kasahara, M.D., Ph.D., has been appointed by the Board of Directors (the “Board”) of 4D Molecular Therapeutics, Inc. (the “Company”) as Chief Scientific Officer of the Company.

View on SEC.gov

4D Molecular Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-001977

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.